In vitro activity:Buparvaquone is significantly selective against L. (L.) infantum chagasi intracellular amastigotes, with an IC50 value of 1.5 μM. In 4-day proliferation assays, buparvaquone efficiently inhibits N. caninum tachyzoite replication(IC50=4.9 nM; IC100=100 nM). Other cutaneous species are also susceptible to buparvaquone, with IC50 values in the range 1-4 μM.In vivo activity:Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduce cutaneous parasite burden and lesion size, compared with the untreated control. Treatment of N. caninum infected mice with buparvaquone (100 mg/kg) either by intraperitoneal injection or gavage prevents neosporosis symptoms in 4 out of 6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treatment. Specification: 10mM in DMSO MDL Number: MFCD01712789 Molecular Formula: C21H26O3 Molecular Weight: 326.43 PubChem CID: 71768 Isomeric SMILES: CC(C)(C)C1CCC(CC1)CC2=C(C3=CC=CC=C3C(=O)C2=O)O
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 10.93 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- B580321-1ml
- CAS:
- 88426-33-9
- Product Size:
- 1ml
